TAF9B promotes esophageal squamous cell carcinoma progression through TBP-dependent transcriptional activation of ADAM17.
Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the common malignant tumors. TATA protein-associated factor 9B (TAF9B) is essential for regulating RNA polymerase II-mediated transcription, and this regulation at the transcriptional level, which is closely related to the carcinogenesis of various tumors, represents a complex process. This study aimed to investigate the expression of TAF9B in ESCC and its potential effect on patient prognosis. Real-time quantitative polymerase chain reaction analysis showed that the expression level of TAF9B was significantly upregulated in ESCC tissues (P = 0.0039). Kaplan-Meier survival analysis demonstrated that patients with low TAF9B expression exhibited better overall survival than those with high TAF9B expression (P = 0.01). This study indicated that TAF9B is highly expressed in ESCC and may have prognostic relevance for ESCC patients. Further studies revealed that TAF9B knockdown could inhibit the proliferation of ESCC cells both in vitro and in vivo. Transcriptome sequencing analysis and validation experiments confirmed that a disintegrin and metalloproteinase 17 (ADAM17) acts as a downstream target gene regulated by TAF9B. Our study demonstrated that TAF9B promotes TATA binding protein occupancy at the ADAM17 promoter and upregulates ADAM17 expression. This process further activates the TNF-α/NF-κB signaling pathway and suppresses apoptosis in ESCC cells. Collectively, TAF9B acts as a novel oncogenic factor in ESCC and promotes tumor progression.